Back to top
more

United Therapeutics (UTHR)

(Delayed Data from NSDQ)

$235.95 USD

235.95
391,825

-1.05 (-0.44%)

Updated Apr 25, 2024 03:59 PM ET

After-Market: $235.99 +0.04 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 251)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for UTHR

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

0 items in cart

United Therapeutics Corporation [UTHR]

Reports for Purchase

Showing records 421 - 440 ( 585 total )

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 421

12/29/2014

Industry Report

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of Dec 29

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 422

12/26/2014

Daily Note

Pages: 5

United Therapeutics Plans to Submit sNDA for Remodulin in January 2015; Reiterate OUTPERFORM and $171 PT.

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 423

12/19/2014

Industry Report

Pages: 5

LIFE SCIENCES AND HEALTH CARE - The Week Ahead in Life Sciences- Upcoming Events for the Week of Dec 22

Provider: WEDBUSH SECURITIES INC.

Price: 10.00

Research Provided by a Third Party

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 424

12/14/2014

Industry Report

Pages: 5

LIFE SCIENCES AND HEALTH CARE

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 425

12/03/2014

Industry Report

Pages: 45

December and 2015 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 426

11/24/2014

Daily Note

Pages: 5

LIFE SCIENCES AND HEALTH CARE

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 427

11/21/2014

Company Report

Pages: 7

Price: 24.95

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 428

11/04/2014

Daily Note

Pages: 46

November and Remaining 2014 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 429

10/30/2014

Company Report

Pages: 9

Q3 Financials Mixed but Long-Term Outlook for Orenitram TiD Better Than We Expected

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 430

10/29/2014

Company Report

Pages: 10

3Q Results Spook at First, But Fundamentals Remain Sound: Reit Buy and $150 PT

Provider: H.C. WAINWRIGHT & CO., INC.

Price: 25.00

Research Provided by a Third Party

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 431

10/27/2014

Company Report

Pages: 8

Price: 24.95

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 432

10/23/2014

Company Report

Pages: 10

Q3 Preview: We Anticipate Strong Revenues in Q3

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 433

10/01/2014

Daily Note

Pages: 46

October and Remaining 2014 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 434

09/29/2014

Industry Report

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of Sept 29

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 435

08/29/2014

Company Report

Pages: 7

''117 Patent Upheld; No Generic Remodulin Until Late 2017. Reiterate OUTPERFORM and Increasing PT to $141 for Increased Remodulin Sales.

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 436

08/26/2014

Daily Note

Pages: 46

September and Remaining 2014 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 437

08/21/2014

Company Report

Pages: 8

Price: 24.95

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 438

08/08/2014

Industry Report

Pages: 47

Emerging Pharmaceuticals - August and 2014 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 439

07/29/2014

Company Report

Pages: 9

Q2 Financials: Across-the-Board Beat and Growth Continues; Reiterate OUTPERFORM and Increasing PT to $133

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 440

07/27/2014

Industry Report

Pages: 6

LIFE SCIENCES AND HEALTH CARE

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party